Patients With Geographic Atrophy and Their Patient Journey in the United States (US)
Geographic AtrophyTo quantify and describe patients with a Geographic Atrophy (GA) diagnosis in at least one eye, and the progression to neovascular Age-Related Macular Degeneration (including how many receive Anti-VEGF), or to GA (in the fellow eye only).
Safety and Efficacy Assessment Treatment Trials of Emixustat Hydrochloride
Geographic AtrophyThe purpose of this study is to determine if emixustat hydrochloride (ACU-4429) reduces the rate of progression of geographic atrophy compared to placebo in subjects with dry age-related macular degeneration.
GTSCOPE - To Evaluate the Natural Progression of Dry Age-related Macular Degeneration (AMD)
Dry Age-related Macular DegenerationMacular Degeneration4 moreAn observational study to evaluate the natural progression of dry AMD in genetically defined subjects
Optical Coherence Tomography and Microperimetry Biomarker Evaluation in Patients With Geographic...
Age-Related Macular DegenerationGeographic Atrophy2 moreThis study is a biomarker evaluation study in patients with geographic atrophy secondary to age-related macular degeneration (AMD). The study evaluates microperimetry (fundus-controlled perimetry) and optical coherence tomography imaging for assessing changes in retinal sensitivity and anatomy over time.
A Comparison of Ranibizumab and Aflibercept for the Development of Geographic Atrophy in (Wet) AMD...
Age-Related Macular DegenerationThe purpose of this study was to compare the development of new geographic atrophy in patients with wet Age-related Macular Degeneration (AMD) when treated with either ranibizumab or aflibercept over 24 months. Geographic atrophy is an advanced form of AMD that can result in the progressive and irreversible loss of visual function over time.
Non Exudative AMD Imaged With SS-OCT
Dry Macular DegenerationThe investigators wish to better understand the role of the choriocapillaris (CC) in the formation and progression of non-exudative in age related macular degeneration (armd) by imaging the retinal pigment epithelium (rpe) and the choroidal microvasculature and by studying their inter-dependence to determine if the loss of the CC could prove useful as an anatomic clinical trial endpoint in future drug trials.
Micropulse Laser for Geographic Atrophy
Geographic AtrophyAge-related Macular DegenerationGeographic atrophy (GA) causes the loss of the retinal pigment epithelium (RPE) cells in broad areas of the retina. The application of subthreshold micropulse laser spots in healthy RPE in the vicinity of the area of GA may restore the imbalance in survival factors caused by the disease (ie, the laser may decrease vascular endothelial growth factor and RPE-derived transforming growth factor beta, upregulation of pigment epithelium-derived factor). This may slow or even stop the enlargement of atrophy secondary to GA, and therefore, avoid further vision loss.
Pharmacokinetic and Pharmacodynamic Study of Emixustat in Subjects With Geographic Atrophy Associated...
Geographic AtrophyAge-Related Macular DegenerationThe purpose of this study is to characterize emixustat hydrochloride pharmacokinetic and pharmacodynamic parameters in subjects with geographic atrophy associated with dry age-related macular degeneration.
Safety and Efficacy of IONIS-FB-Lrx in up to 120 Patients 55 and Older With Geographic Atrophy (GA)...
Geographic AtrophyAge Related Macular DegenerationThe purpose of this study is to assess the Safety and Efficacy of IONIS-FB-Lrx for up to 120 patients with Geographic Atrophy secondary to Age Related Macular Degeneration
Efficacy and Safety Study of CNTO 2476 in Participants With Visual Acuity Impairment Associated...
Visual AcuityGeographic Atrophy1 moreThe purpose of the study is to evaluate the efficacy and safety of CNTO 2476 cells administered into the subretinal space by the suprachoroidal surgical approach and the subretinal access kit (SRAK-02) in participants with visual acuity impairment associated with Geographic Atrophy (GA) secondary to Age Related Macular Degeneration (AMD).